Christopher M. Reynolds

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Brian G.M. Durie, Antje Hoering, Muneer H. Abidi et al. · The Lancet · 2016 · 888 citations

Medicine, Hematology, Oncology +16

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Brian G.M. Durie, Antje Hoering, Rachael Sexton et al. · Blood Cancer Journal · 2020 · 252 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)

Han‐Seung Yoon, Nathan R. Foster, J. Meyers et al. · Annals of Oncology · 2015 · 57 citations · Full text

Medicine, Oncology, Pharmacology +15

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Brian G.M. Durie, Antje Hoering, S. Vincent Rajkumar et al. · Blood · 2015 · 56 citations

Medicine, Hematology, Pharmacotherapy +16

ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP

Grzegorz S. Nowakowski, Fangxin Hong, David W. Scott et al. · Hematological Oncology · 2019 · 35 citations

Medicine, Hematology, Oncology +16